Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.09 USD
Change Today +0.02 / 1.87%
Volume 353.8K
PLX On Other Exchanges
Tel Aviv
As of 10:43 AM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2 Snunit Street

Science Park

POB 455

Carmiel, 21000


Phone: 972 4 988 9488

Fax: 972 4 988 9489

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system (ProCellEx). Using its ProCellEx system, the company is developing a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of action. The company’s initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. Product Pipeline PRX-102: PRX-102, or alpha-GAL-A, is a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans, is in an ongoing phase I/II clinical trial. PRX-106: PRX-106, its oral Anti-TNF (Tumor, Necrosis Factor) product candidate which is being developed as an orally-delivered anti inflammatory treatment using plant cells as a natural capsule for the expressed protein. PRX-110: PRX-110 is a proprietary plant cell recombinant human Deoxyribonuclease 1 (DNase), under development for the treatment of cystic fibrosis, to be administered by inhalation. PRX-112: PRX-112 is an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant GCD (glucocerebrosidase) enzyme produced and encapsulated within carrot cells. Except for the rights to commercialize taliglucerase alfa worldwide (other than Brazil and Israel), which the company licensed to Pfizer Inc., the company holds the worldwide commercialization rights to all of its proprietary development candidates. Strategy The company’s strategy centers around prioritizing existing and new pipeline candidates to focus on clinically superior products that offer a clear competitive advantage over existing treatments. Its strategy includes the following: aggressively push PRX-102 through clinical development; initiate clinical efficacy trials of oral Anti-TNF; initiate clinical efficacy trials of AIR DNase for the treatment of Cystic Fibrosis (CF); focus on improving the product candidate’s formulation and delivery in order to transform it into a commercially viable product; and expand pipeline by leveraging the advantages of proprietary ProCellEx protein expression technology. Intellectual Property As of December 31, 2014, the company held, or had license rights to 64 patents and 95 pending patent applications with respect to various compositions, methods of production and methods of use relating to ProCellEx protein expression system and its proprietary product pipeline. As of December 31, 2014, the company held, with a third party, one joint patent and one joint patent application, and licensed rights to two patents. Trademark ProCellEx is the company’s registered trademark. Competition The company competes with Actelion Ltd. Competitors developing alternative expression technologies include Crucell N.V. (which was acquired by Johnson & Johnson during 2010), Shire and GlycoFi, Inc. (which was acquired by Merck & Co. Inc.). History Protalix BioTherapeutics, Inc. was founded in 1993.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLX:US $1.09 USD +0.02

PLX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PLX.
View Industry Companies

Industry Analysis


Industry Average

Valuation PLX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PROTALIX BIOTHERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at